Prospective Study In Noninvasive Evaluation of Hepatic Fibrosis in Chronic Hepatitis B
NCT ID: NCT01679769
Last Updated: 2015-11-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
818 participants
OBSERVATIONAL
2012-05-31
2015-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Stuy in Evaluating Hepatic Fibrosis Related to Hepatitis B Virus Using Non-invasive Parameters
NCT01962155
Comparison of Hepatus and FibroScan for Evaluation of Fibrosis and Steatosis
NCT05786963
MR Elastography for Assessing Liver Fibrosis in Chronic Hepatitis B
NCT06779058
FibroTouch Non-invasive Evaluation of Liver Fibrosis and Cirrhosis
NCT02476695
68Ga-FAPI PET/CT in Liver Fibrosis Patients
NCT04533828
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* agree to have liver biopsy
Exclusion Criteria
* liver diseases due to other origin
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Municipal Science & Technology Commission
OTHER
Peking University First Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Guiqiang Wang
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Guiqiang Wang, MD
Role: PRINCIPAL_INVESTIGATOR
Peking University First Hospital
Hong Zhao, MD
Role: STUDY_DIRECTOR
Peking University First Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University First Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
81170386
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
2012-455
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.